PsiOxus-Therapeutics News-Web-12_edited.jpg

Our News

Read about our latest news, events and updates

August 11, 2022

PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer

September 15, 2021

PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

April 14, 2021

PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases

April 7, 2021

PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration

March 5, 2020

PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer.